2nd NovAliX Conference - Biophysics in Drug Discovery 2015

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

BφDD 2015

 Strasbourg, France    June 9-12, 2015

Scientific Programme


11:00

Registration

13:30

Welcome Address

SESSION 1: Method Development & Emerging Technologies

Session Chair

Dr Johannes OTTL
NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland

13:45

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Dr Pär NORDLUND
KAROLINSKA INSTITUTE & NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore

14:30

No Crystal, No Problem: Hydrogen Deuterium Exchange Mass Spectrometry in Drug Discovery

Dr Nino CAMPOBASSO
GLAXOSMITHKLINE, Collegeville, United States

15:15

Strategies to Target Protein-Protein Interactions

Dr Marta WESTWOOD
UCB, Slough, United Kingdom

15:40

Coffe break & exhibition

16:10

Characterization of IL17A Inhibitors by Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS)

Mr Alfonso ESPADA
ELI LILLY, MADRID, Spain

16:35

Second-Harmonic Generation (SHG) Measures and Resolves Protein Conformations: High-Throughput Structural Drug Discovery

Dr Joshua SALAFSKY
BIODESY, South San Francisco, United States

KEYNOTE LECTURE

Chair

Dr Ursula EGNER
BAYER, Berlin, Germany

17:20

Molecular Recognition in Protein-Ligand Complexes

Prof. Gerhard KLEBE
PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany

18:20

Welcome Reception

19:35

End of Day 1

08:30

Registration

SESSION 2: Biophysics for Integral Membrane Proteins

Session Chair

Dr Vincent MIKOL
SANOFI, Vitry-sur-Seine, France

09:00

Improving the Biophysical Properties of GPCRs for Drug Screening and Structural Biology

Prof. Andreas PLÜCKTHUN
UNIVERSITY OF ZÜRICH, Zurich, Switzerland

09:45

Fluorine NMR Screening: Principles and Application to a Membrane Protein

Dr Claudio DALVIT
UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland

10:30

Coffee break & exhibition

11:00

Drug Discovery at the Single Molecule Level

Dr Anders GUNNARSSON
ASTRAZENECA, Mölndal, Sweden

11:25

First Crystal Structure of Transmembrane Domain of G-Protein-Coupled Receptor MGLU5 Provides Insight Into Efficient New Drugs Design

Dr Krzysztof OKRASA
HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom

SESSION 4 (anticipated): The Use of Kinetics in Drug Discovery

Session Chair

Dr Geoff HOLDGATE
ASTRAZENECA, Macclesfield, United Kingdom

11:50

Towards a Better Understanding of the Structural Mechanisms of Kinase Inhibitor Binding Kinetics

Prof. Stefan KNAPP
OXFORD UNIVERSITY, Oxford, United Kingdom

12:35

Lunch, exhibition & networking

SESSION 3: Impact of Biophysics on Drug Discovery Projects

Session Chair

Dr Herbert NAR
BOEHRINGER INGELHEIM, Biberach, Germany

14:15

Some Examples of Biophysics Helping Drug Discovery

Prof. Rod HUBBARD
UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom

15:00

Making Every Interaction Count: Impact of Biophysical Methods Across the AstraZeneca Small-Molecule Portfolio

Dr Stefan GESCHWINDNER
ASTRAZENECA, Mölndal, Sweden

15:45

Coffee break & exhibition

16:15

Biophysical Approaches for Hit Finding and Evaluation at Bayer

Dr Ursula EGNER
BAYER, Berlin, Germany

17:00

Biophysics and Structural Biology Enabling the Discovery of Therapeutic Solutions: from Small Molecule Inhibitors to Vaccine Design

Dr Vincent MIKOL
SANOFI, Vitry-sur-Seine, France

17:45

End of Day 2

SESSION 4: The Use of Kinetics in Drug Discovery

Session Chair

Dr Geoff HOLDGATE
ASTRAZENECA, Macclesfield, United Kingdom

09:15

CCR2 Antagonists: From Structure-Kinetics Relatiosnhips to in vivo Efficacy

Dr Laura HEITMAN
UNIVERSITY OF LEIDEN, Leiden, The Netherlands

10:00

A Universal Homogeneous Assay for High-Throughput Determination of Binding Kinetics

Dr Amaury Ernesto FERNANDEZ MONTALVAN
BAYER, Berlin, Germany

10:25

Coffee break & exhibition

10:55

CDK8 Inhibitors with Long Residence Time Emerging from a Retro-Design Approach: New Opportunities for Cancer Treatment

Dr Anita WEGERT
MERCACHEM-SYNCOM, Nijmegen, The Netherlands

11:20

Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure

Dr Herbert NAR
BOEHRINGER INGELHEIM, Biberach, Germany

12:05

Lunch, exhibition & networking

13:45

Poster Session

16:00

Coffe break & exhibition

16:30

Round Table Discussion
The Round Table will sum up the topics discussed in the first four Sessions of this Conference

Chair

Prof. Rod HUBBARD
UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom

17:15

Poster Prizes

17:25

End of Day 3

20:00

Conference Dinner at the Restaurant Maison Kammerzell
(optional, subject to prior booking)

SESSION 5: Special Focus on Epigenetics

Session Chair

Prof. Helena DANIELSON
UPPSALA UNIVERSITY, Uppsala, Sweden

09:15

Interrogating the Bromodomain Family Through Chemical Biology

Dr Richard CUMMINGS
CONSTELLATION PHARMACEUTICALS, Cambridge, United States

10:00

When to get Biophysical with Readers, Writers and Erasers

Dr Chun-wa CHUNG
GLAXOSMITHKLINE, Stevenage, United Kingdom

10:45

Coffee break & exhibition

11:15

Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics

Dr Robert A. COPELAND
EPIZYME, Cambridge, United States

12:00

Closing Remarks

12:15

End of Day 4

14:15

Guided tour of the Cathedral of Strasbourg
(subject to prior registration)